1. Antimalarial use in COVID-19 patients requires close monitoring

   News item 02 May 2020 Pages: 1 - 1

2. EMA: risks of ingenol mebutate use outweigh its benefits

   News item 02 May 2020 Pages: 2 - 2

3. Health Canada: thiamazole linked with risk of vasculitis

   News item 02 May 2020 Pages: 3 - 3

4. Need to improve pharmacovigilance of herbal and traditional medicines

   Comment 02 May 2020 Pages: 4 - 4

5. ACEI inhibitors and ARBs do not increase severity of COVID-19

   Clinical study 02 May 2020 Pages: 5 - 5

6. Aspirin use associated with depression

   Clinical study 02 May 2020 Pages: 6 - 6

7. High incidence of ADRs in COVID-19 patients in China

   Clinical study 02 May 2020 Pages: 7 - 7

8. Label discrepancies between originator and generic drugs impact safety

   Clinical study 02 May 2020 Pages: 8 - 8

9. Neurological disorders after in utero exposure to antiretrovirals

   Clinical study 02 May 2020 Pages: 9 - 9

10. Renal failure increases risk of anticoagulant-related haemorrhage

    Clinical study 02 May 2020 Pages: 10 - 10

11. Safety concerns with higher dosage chloroquine in COVID-19 patients

    Clinical study 02 May 2020 Pages: 11 - 11

12. Suboptimal agreement between clinician and patient reporting of AEs

    Clinical study 02 May 2020 Pages: 12 - 12

13. Tedizolid has better tolerability than linezolid

    Clinical study 02 May 2020 Pages: 13 - 13

14. Other adverse reaction research

    News item 02 May 2020 Pages: 14 - 14

15. Acetylcysteine/paracetamol

    Case report 02 May 2020 Pages: 15 - 15

16. Afatinib/erlotinib/gefitinib

    Case report 02 May 2020 Pages: 16 - 16

17. Alcohol

    Case report 02 May 2020 Pages: 17 - 17

18. Alemtuzumab

    Case report 02 May 2020 Pages: 18 - 18

19. Alemtuzumab

    Case report 02 May 2020 Pages: 19 - 19

20. Alemtuzumab

    Case report 02 May 2020 Pages: 20 - 20

21. Alemtuzumab

    Case report 02 May 2020 Pages: 21 - 21

22. Alemtuzumab

    Case report 02 May 2020 Pages: 22 - 22

23. Alemtuzumab

    Case report 02 May 2020 Pages: 23 - 23

24. Alemtuzumab

    Case report 02 May 2020 Pages: 24 - 24

25. Alemtuzumab/prednisone

    Case report 02 May 2020 Pages: 25 - 25

26. Alemtuzumab/teriflunomide

    Case report 02 May 2020 Pages: 26 - 26

27. Alendronic acid/methylprednisolone/prednisone

    Case report 02 May 2020 Pages: 27 - 27

28. Allergy-immunotherapies

    Case report 02 May 2020 Pages: 28 - 28

29. Amino-acids/glucose/lipid-emulsion

    Case report 02 May 2020 Pages: 29 - 29

30. Amiodarone

    Case report 02 May 2020 Pages: 30 - 30

31. Amiodarone/dobutamine

    Case report 02 May 2020 Pages: 31 - 31

32. Amitriptyline/duloxetine interaction

    Case report 02 May 2020 Pages: 32 - 32

33. Amlodipine/captopril/doxazosin overdose

    Case report 02 May 2020 Pages: 33 - 33

34. Amoxicillin/clavulanic-acid

    Case report 02 May 2020 Pages: 34 - 34

35. Amphotericin-B-liposomal

    Case report 02 May 2020 Pages: 35 - 35

36. Amphotericin-B/methylprednisolone

    Case report 02 May 2020 Pages: 36 - 36

37. Anti-CD19-CAR-transduced-T-cells/pembrolizumab

    Case report 02 May 2020 Pages: 37 - 37

38. Anti-thymocyte globulin

    Case report 02 May 2020 Pages: 38 - 38

39. Antibacterials

    Case report 02 May 2020 Pages: 39 - 39

40. Antibacterials

    Case report 02 May 2020 Pages: 40 - 40

41. Antibacterials/immunosuppressants/hydrocortisone

    Case report 02 May 2020 Pages: 41 - 41

42. Anticoagulants/antiplatelets

    Case report 02 May 2020 Pages: 42 - 42

43. Antihypertensives/digoxin/rivaroxaban

    Case report 02 May 2020 Pages: 43 - 43

44. Antineoplastics

    Case report 02 May 2020 Pages: 44 - 44

45. Antineoplastics

    Case report 02 May 2020 Pages: 45 - 45

46. Antineoplastics

    Case report 02 May 2020 Pages: 46 - 46

47. Antineoplastics

    Case report 02 May 2020 Pages: 47 - 47

48. Antineoplastics

    Case report 02 May 2020 Pages: 48 - 48

49. Antineoplastics

    Case report 02 May 2020 Pages: 49 - 49

50. Antineoplastics

    Case report 02 May 2020 Pages: 50 - 50